Aim: Surgery is the only modality of cure in patients diagnosed with neuroendocrine tumours (NETs). The aim of this study was to identify prognostic factors associated with disease relapse in patients with NETs treated by potentially-curative surgery. 2.6, 95%-CI 1.1-6.3, p=0.052), grade (Ki-67%-based) (HR-2.5; 95%-CI 1.4-4.7; p=0.003) and perineural invasion (HR-2.1; 95%-CI 1.1-3.9; p=0.029) were prognostic for relapse. Factors remaining significant after multivariable analysis were tumour size (HR-1.67; 95%-CI 1.04-2.70; p=0.03), nodal involvement (HR-2.61; 95%-CI 1.17-5.83; p=0.013) and Ki-67 at the time of diagnosis (HR-1.93; 95%-CI 1.24-3.0; p=0.002).
Introduction
A diagnosis of neuroendocrine tumour (NET) is rare, representing 0.5% of all malignancies [1] . However, published studies show that a diagnosis of NET is increasing [2, 3] .
The five-year overall survival varies widely (19-93%) , depending on prognostic factors [1] .
This percentage is about 82-92% for patients with curatively resected pancreatic NETs [4, 5] .
About two thirds of NETs are of gastrointestinal or pancreatic origin [3] and 12-22% of all patients with a NET diagnosis present with metastatic disease [1] .
As with most cancers, resection is the primary treatment for a localised NET. If distant metastases are present, it is possible in some cases to perform resection of the primary tumour and metastases with curative intent [6] .
Despite curative intent, relapse occurs frequently in patients with NET. The overall five year relapse-free survival after potentially curative surgery is about 60% [7, 8] , although this rate is worse for pancreatic NETs [7, 8] . To our knowledge, seven studies have been published evaluating prognostic factors for relapse after potentially curative resection of NETs [4, 7, [9] [10] [11] [12] [13] , in cohorts varying between 53 and 263 patients. Only one study included all primary locations of NET [7] . As these studies report differing results, we cannot draw firm conclusions as to which are the predominant prognostic factors for relapse after potentially curative resection of NET. Moreover, there are no established adjuvant therapies to date which have been shown to improve relapse-free or overall survival following surgery. The role of chemotherapy in the treatment of patients with NETs has mostly been investigated in those with metastatic disease, and demonstrated more efficacy in those with higher grade tumours [14] . In patients with advanced well differentiated pancreatic neuroendocrine tumours, streptozotocin seems most effective [14] . However, the combination of temozolomide with capecitabine has also shown promise [15] . Studies utilising chemotherapy in patients with advanced gastrointestinal neuroendocrine tumours are predominantly retrospective and have low patient numbers with a consequent lack of control group inclusion [14] . The potential for the use of adjuvant intraoperative post-dissectional tumour bed chemotherapy -has recently been reported and may be an interesting development [16] .
The aim of this current study was to determine the prognostic factors for disease relapse, following potentially curative surgery for NET, over an approximate 12-year period. The information gleaned from this study may enable informed proposals for adjuvant clinical trials in NET patients who have had definitive surgery. Currently, adjuvant systemic therapy does not play any role in the treatment of resectable, well differentiated NETs [6] .
Patients and Methods

General
All patients registered with The Christie ENETS Centre of Excellence, with grade (G) 1 or G2 NETs who had undergone curative surgery between February 2002 and June 2014 were included in this retrospective analysis. Research was carried out as per local institutional ethical guidelines.
All patients with NETs were identified from the local records and screened for eligibility.
Inclusion criteria for patients in this study were: all patients with an age ≥16 years at the time of diagnosis, treated with potentially curative R0 or R1 resection with a histological diagnosis of a well differentiated grade (G) 1 or grade 2 NET (Ki-67 ≤20%). Curative surgery was defined as surgery for local disease, or advanced/metastatic disease which was also considered potentially curable by surgery.
If histological diagnosis was known prior to surgery and patients did not present as an emergency, all patients had staging imaging (CT scan, MRI liver as appropriate and Octreotide scan), biochemical and haematological blood tests, and serum chromogranin (CgA)/serum 5-hydroxyindoleacetic acid (5-HIAA).
Patients with R2 resections and patients with unknown R status, G3 NETs, mixed adenoneuroendocrine carcinomas and goblet cell carcinoids were excluded.
Data that was retrospectively analysed, by case note review, and included date of birth and diagnosis, date of surgery, primary tumour location, TNM stage, grade including Ki-67 index, presence of vascular invasion, presence of perineural invasion, necrosis, R0 or R1 resection, hormone production, genetic predisposition for NET, presence of multiple NETs, presence of other active malignancy, adjuvant treatment, Eastern Cooperative Oncology Group (ECOG) [17] performance status and Adult Comorbidity Evaluation (ACE) [18] score, date of relapse including site (when applicable), date and cause of death (when applicable).
Pathological review was carried out on all cases at The Christie but there was still nonavailability of some details.
Primary tumour localisation was divided into small bowel, colon/caecum/rectum, appendix, pancreas, bronchopulmonary and others (gastric and ovarian NET). For staging and grading, the ENETS guidelines were used [19, 20] , [21] . Functionality was also recorded. Serum 5-HIAA and CgA levels were recorded. In this study, an R0 resection indicated that all the resection margins were free of tumour, an R1 resection was recorded when resection margins were involved by tumour, or tumour involvement was within 1 mm.
At The Christie, follow-up investigations were performed according to the most recent ENETS guidelines [22] , with follow-up CT imaging and/or octeotride scans performed postsurgery.
Statistics
All data were analysed using the statistical programmes Stata 13 and IBM SPSS Statistics, version 22.
Results were presented as frequencies and percentages and as median (range) for continuous variables. Relapse-free survival (RFS) was defined as the time between surgical resection and date of last follow-up or date of death without any evidence of relapse. In cases of second resection (appendix primary), RFS was defined as time between second surgical resection and date of last follow-up or date of death without any evidence of relapse.
Overall survival (OS) was defined as the time between surgical resection and date of last follow-up or death. The Kaplan-Meier method was used to analyse RFS and OS. Median RFS rates were estimated and 5-year RFS and OS were plotted. For patients with nonavailability of information for a specific factor, data was censored in the univariate analysis.
Cox-regression was used for the univariate analyses. The partial likelihood ratio test was used to identify p values. Additional p values related to RFS were calculated using the 'logrank' test. All exploratory variables were included in the multivariable model and were fitted via a Cox regression. A backward elimination was performed from a full model in the subset of cases with complete data. Variables were sequentially eliminated if their p-value after adjustment for the other variables in the model was >0.1.
Results
Demographics
In total, out of 795 patients with a diagnosis of NET, 188 patients were eligible (well differentiated NET and R0 or R1 resection) ( Figure 1 ). The median post-operative follow-up time was 2.6 years (range 0.1-12.7 years).
Figure 1: Enrolment of patients
The characteristics of the 188 patients are summarised in table 1. The median age at time of surgery was 60 years (range 16-89), 91 (48%) were male. The most frequent primary location of NET in this cohort was the small bowel (n=61; 32.4%), followed by the pancreas (n=54; 28.7%) and the appendix (n=30; 16.0%). Table 2 provides information about stages at time of diagnosis for the three most predominant primary sites; small bowel was diagnosed at a more advanced stage. The presence of multiple NETs was observed in 18 cases (9.6%) and in 33 cases (17.6%) a second malignancy was present, such as breast cancer or prostate cancer.
The majority of patients had G1 well differentiated NETs (n=138; 73.4%). Vascular invasion (n=75; 39.9%) was more often observed than perineural invasion (n=50; 26.6%). Vascular invasion and perineural invasion were unknown in 18 cases (9.8%). Tumour necrosis was only reported in 10 cases (5.3%) and in 9 cases (4.8%) tumour necrosis was unknown. The resection margin status was R0 in 155 patients (82.4%).
Patients had one surgical resection in 176 cases (93.6%). More than one surgical procedure was performed in 12 cases (6.4%), of which the most common scenario was an incidental finding of NET in the appendix, discovered by emergency laparotomy, needing additional surgery. Adjuvant therapy (chemotherapy) was rarely given in this cohort (n=2; 1.1%).
Relapse
A total of 43 relapses occurred in the cohort of 188 patients after a median follow-up time of 2.6 years (range 0.2-9.4 years). Eighteen relapses occurred in the small bowel (out of 61; 30%), none in colon/caecum/rectum (out of 13), two in the appendix (out of 30; 7%), 17 in the pancreas (out of 54; 31%), three in bronchopulmonary (out of 17; 18%) and three in the "others" subgroup (out of 13; 23%). The majority of the relapses were distant metastases (n=38; 88.4%). Local relapse occurred in five patients (11.6%).
The median RFS for the whole cohort was 8.0 years (95% CI 5.9-10.0 years) and the estimated 5 year RFS was 62.1%. Thirty six relapses (83.7%) occurred within the first five years after surgery. The longest time between surgery and relapse was 9.4 years.
Cox-regression univariate analysis was performed and included the following variables ( 
Overall Survival
Twenty-one patients (11.2%) died during follow-up. Median OS was 7.6 years for patients with relapses and not reached for patients without relapses. The estimated 5-year OS was 86.4%.
No post-operative mortality was observed. The cause of death in the majority of the 21 patients who died was unrelated to the diagnosis of NET in eleven patients (52.9%); eight (38.1%) patients died secondary to their diagnosis of a NET and in two (9.0%) cases, the reason for death was unknown.
Multivariable analysis (relapse)
All exploratory variables were included in the Cox-regression multivariable analysis. A backward elimination was performed from a full model in the subset of cases with complete data (153 cases with 37 relapses). Remaining prognostic factors in the multivariable model were primary tumour location, ENETS stage and Ki-67 index (table 4) .
Factors identified as independent prognostic factors for relapse were size of tumour (HR and Ki-67 index (HR 1.93; 95% CI 1.24-3.0; p=0.002). An elevated risk for relapse could not be confirmed for patients with distant metastases at the time of diagnosis (HR 2.59; 95% CI 0.97-6.97; p=0.079). Also, primary site was not confirmed as a significant prognostic factor for relapse (p=0.010). 
Discussion
The aim of this study was to identify factors associated with disease relapse in patients with a diagnosis of NET, resected with curative intent. Tumour size, nodal involvement and Ki-67 index were identified as independent risk factors.
The median age of patients included in this study was 60 years. This is older than reported in Dieckhoff et al. [7] , which reported a median age of 52 years and also included different primary NET locations. Disease-specific studies reported median ages between 55-59
years [4, [9] [10] [11] [12] [13] .
The median RFS and 5-year RFS in the current study were 8.0 years and 62%, respectively in keeping with other studies [7, 23] . Surprisingly, the subgroup pancreatic NET had a similar RFS as the small bowel subgroup. Pancreatic NET has previously been reported as having a worse outcome compared to other primary sites [7, 8] . In our study, the small bowel subgroup was diagnosed at a more advanced stage than pancreatic NET and was probably due to referral bias, with potentially the majority of patients with pancreatic NETs being referred to this centre (through a centralised hepatobiliary service model), but only the more challenging cases of small bowel NETs (through a non-centralised intestinal surgery model). The nonidentification of primary site as an independent risk factor may alternatively have been a type II error and may be a reflection of patient numbers included.
This study included patients with R0 and R1 resections, which is likely to be a more accurate representation of NET patients treated in the clinical setting than studies which only included patients with R0 resections [7] . The difference in RFS between patients who had R0 or R1
resections was not significant in our study. Similarly, other studies did not prove a relationship between surgical margin status and RFS [9, 11, 12] .
The TNM system proposed by ENETS [19, 20] was prognostic for relapse in our study, however an independent relationship between distant metastases at time of diagnosis and RFS could not be confirmed. The absolute number of patients included with distant metastases at time of diagnosis was only 11 (6%), which might be too small to confirm an independent correlation.
Our study included NETs arising in patients with genetic syndromes. One study mentioned MEN syndrome as prognostic for relapse [4] . We were not able to confirm this factor as our sample size was too small to draw firm conclusions.
The relationship between vascular invasion and relapse were also investigated, which did not show a significant correlation. Many studies revealed this as a prognostic factor for relapse in univariate analysis but were not able to confirm this on multivariable analysis [7, [9] [10] [11] . In the present study, perineural invasion was prognostic for RFS on univariate analysis, this was not confirmed on multivariable analysis. Boninsegna et al. [9] did confirm a relationship between perineural invasion and relapse in univariate analysis, but were not able to confirm this on multivariable analyses. Tumour necrosis was not a prognostic factor for relapse in the present study, although this number was small (n=10; 5%). Hochwald et al. [10] did have greater numbers of patients with tumour necrosis and was thus able to confirm a relationship between tumour necrosis and relapse.
As mentioned by Dieckhoff et al. [7] , the ENETS guidelines for follow-up of patients following curative resection of NET do not provide a uniform recommended follow-up time [24] [25] [26] . In our study, 16% of the relapses occurred more than five years after treatment, which might be an underestimated percentage because of the length of follow-up. Relapses more than five years after treatment were also reported in 24% of the patients in the study by Dieckhoff et al. [7] and in 35% of the patients in the study of Casadei et al. [4] . Also Le Roux et al.
mentioned late relapses [13] . We would suggest a follow-up of at least 10 years, depending on prognostic factors. Most relapses were with distant metastases (88%), which was also demonstrated by other studies.
The current study has limitations; firstly, it was retrospective with consequent non-availability of some data. The second limitation of this study was the potential for referral bias. Our institution is a specialised treatment centre and may thus treat patients with a more complex history and this may not be a complete reflection of those patients having curative resection.
However, as this has been an ENETS Centre of Excellence since 2011, the vast majority of patients are now likely to be referred to the tumour board at this institution, but this may not have been the case in earlier years, before this accreditation. The referral trend also caused an unequal distribution of patients referred over the years, and it was not possible to compare outcomes for patients treated in different time periods due to number limitation.
Finally, the median follow-up of patients in our study was 2.6 years (range 0.1-12.7), and as our study focused on patients with well differentiated G1 or G2 NET, the duration of follow-up was relatively short. This may be somewhat attributable to the referral trend, with more referrals received in the more recent era.
Despite the limitations, this study is to our knowledge one of the largest studies reporting on prognostic factors in patients following curative-intent surgery with a diagnosis of NET, where patients with differing primary sites were included. There are difficulties in carrying out studies looking at a single primary site due to the rarity of the condition despite this being an ENETs centre of Excellence. The data gained from this study should facilitate identification of subgroups of patients with a diagnosis of NET who may develop relapse after resection done with curative intent. This experience is required to enable advancement of this field and awareness of the prognostic factors for relapse will be important in selecting patients for future adjuvant trials in the speciality of NETs.
Conclusion
In conclusion, the size of tumour, lymph node involvement and Ki-67 index were independent prognostic factors for relapse after potentially curative surgery in patients with a diagnosis of a NET. Adjuvant strategies and well-designed studies should be considered in the higher risk groups. As late relapses are common, follow-up should be extended to at least 10 years.
